Axel Bolte studied at ETH and St Gallen Business School in Switzerland. After a very successful career at HBM Partners AG, he co founded Inozyme in 2015 and is the current CEO. Inozyme is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. They raised US$ 116 M in private financing and went public on the NASDAQ in July 2020.

Axel was part of and has built the team at Inozyme from day one. With his family in Switzerland and the company in Boston he understands what remote work entails. His team is considered to be world class and Axel will share with us his journey of: Building the team at Inozyme.